Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials

Objective: To evaluate the safety of daily oral ospemifene 60 mg, estrogen agonist/antagonist, used to treat moderate-to-severe dyspareunia due to postmenopausal vulvovaginal atrophy, which is part of genitourinary syndrome of menopause. Methods: Post hoc analysis of safety data (treatment-emergent...

Descripción completa

Detalles Bibliográficos
Autores principales: Simon, James A., Altomare, Corrado, Cort, Susannah, Jiang, Wei, Pinkerton, JoAnn V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5771532/
https://www.ncbi.nlm.nih.gov/pubmed/29064335
http://dx.doi.org/10.1089/jwh.2017.6385

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5771532/
https://www.ncbi.nlm.nih.gov/pubmed/29064335
http://dx.doi.org/10.1089/jwh.2017.6385

Ejemplares similares